Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients - PubMed
4 days ago
- #immunotherapy
- #type 1 diabetes
- #teplizumab
- First Italian experience with teplizumab under compassionate use for adults with Stage 2 type 1 diabetes (T1D).
- Three adult women (20-40 years) received a 14-day intravenous course of teplizumab in a day-hospital setting.
- Treatment was well tolerated with minor side effects: transient transaminase elevation, lymphopenia, and mild cytokine-release syndrome in one patient.
- All patients maintained stable glycaemic control and preserved β-cell function at 3-month follow-up.
- Teplizumab administration proved feasible and safe in a real-life academic context, consistent with pivotal trial data.
- Highlights the importance of a structured multidisciplinary approach for early disease-modifying immunotherapy in presymptomatic T1D.